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Received August 25, 2011; accepted February 7, 2012AbstractBackground: Ankylosing spondylitis (AS) is a chronic arthritis with a pathogenesis which is not fully understood. A third subset of IL-17-
producing T helper cells, called Th17 cells, has been discovered and characterized. We investigated whether IL-17 and IL-23, two Th17-
related cytokines, play any roles in the pathogenesis of, and have any correlations with, disease activity and clinical manifestations in AS.
Methods: This cross-sectional study included 49 AS patients and 25 healthy control subjects. The serum IL-17 and IL-23 levels were measured using
enzyme-linked immunosorbent assay kits. At the same time, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Bath Ankylosing
SpondylitisDiseaseActivity Index (BASDAI),BathAnkylosingSpondylitisFunctional Index (BASFI) andBathAnkylosingSpondylitisPatientGlobal
Score (BAS-G) levels were measured, and physical examinations were performed on study participants to determine their extent of physical mobility.
Results: The serum IL-17 and IL-23 levels of the AS patients were significantly higher than those of the healthy controls. In the AS patients, the
BASDAI scores had a better correlation with the serum IL-17 or IL-23 levels (IL-17, r ¼ 0.351, p ¼ 0.014; IL-23, r ¼ 0.398, p ¼ 0.005) than
with ESR (r ¼ 0.078, p ¼ 0.600) and CRP (r ¼ 0.012, p ¼ 0.993). IL-17 or IL-23 correlate to the BASFI, BAS-G and parameters related to
physical mobility. In the receiver operating characteristic (ROC) analysis, the serum IL-17 and IL-23 levels act better in discriminating patients
with BASDAI4 (AUC value 0.88, p ¼ 0.001) than ESR and CRP (AUC value 0.727, p ¼ 0.008).
Conclusion: Serum IL-17 and IL-23 levels were significantly higher in AS patients than in healthy controls and the levels correlate to disease
activity measured by BASDAI scores, but not parameters of functional ability and spinal mobility. These results suggest the existence of a role of
IL-17 and IL-23 in the pathogenesis of inflammation in AS.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Spondyloarthritis (SpA) is a family of chronic arthritis
diseases characterized by inflammatory back pain, peripheral* Corresponding author. Dr. Chung-Tei Chou, Division of Allergy, Immu-
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http://dx.doi.org/10.1016/j.jcma.2012.05.006arthritis, and enthesitis.1 It comprises five major subtypes,
including ankylosing spondylitis (AS), reactive arthritis,
psoriatic arthritis (PsA), arthritis associated with inflammatory
bowel disease, and undifferentiated spondyloarthritis. AS is
the prototype of spondyloarthritis, and it predominantly
involves the axial joints and bilateral sacroiliac joints. AS
occurs predominantly in young adult males and has a strong
association with human leukocyte antigen (HLA)-B27. Thehinese Medical Association. All rights reserved.
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of tumor necrosis factor-a (TNF-a) was proven by its
increased level in serum and sacroiliac joint and the dramatic
response after anti-TNF-a therapy.2,3
Recently, the discovery of CD4 þ Th17 T cells and the
interleukin-23 (IL-23) /IL-17 axis has challenged the existing
paradigms and the role of Th1 T cells in many autoimmune
diseases.4 Th17 is a third CD4 þ T effector subset charac-
terized by the production of IL-21, IL-22, TNF-a and IL-17,
the hallmark proinflammatory cytokine. Other than host
defense, IL-17 has been proven to be critical in the patho-
genesis of various autoimmune diseases such as rheumatoid
arthritis (RA), systemic lupus erythematosus, systemic scle-
rosis, psoriasis and inflammatory bowel disease.5e9
IL-23 is a member of the IL-12 family, which is composed
of p40 and p19 subunits, in contrast to the p35/p40 hetero-
dimer which forms the bioactive IL-12. IL-23 not only syn-
ergizes with IL-6 and IL-1 to promote Th17 development, but
also stimulates Th17 expansion and prolongs IL-17 produc-
tion.10 A growing body of evidence has revealed the possible
role of the IL-23/IL-17 axis in the pathogenesis of AS.11e14 In
RA, the serum IL-17 levels correlated strongly with disease
activity and CRP concentration.15 The correlation of IL-17 and
IL-23 with AS disease activity, function and spinal mobility is
not fully known. In this study, other than comparing the serum
levels of IL-23 and IL-17 between AS patients and healthy
controls, we investigated the relationship of the two serum
cytokine levels with parameters related to disease activity,
function and spinal mobility.
2. Methods2.1. PatientsA total of 49 ethnic Chinese AS patients, who fulfilled the
1984 modified New York criteria, were consecutively enrolled
from the outpatient department of the Division of Allergy,
Immunology, and Rheumatology, Taipei Veterans General
Hospital.16 As a control group, blood samples were obtained
from 25 age- and sex-matched healthy ethnic Chinese
controls. This research was approved by the ethics committee
of Taipei Veterans General Hospital. Before the study,
informed consent was obtained from all participants.2.2. Study designClinical and laboratory assessments of the patients were
performed on the same day. We evaluated the disease
activity, functional ability and the AS patients’ global
assessment using the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), Bath Ankylosing Spondylitis
Functional Index (BASFI), and Bath Ankylosing Spondylitis
Patient Global Score (BAS-G), with visual analog scale.
Meanwhile, physical examinations were performed on the
subjects to determine physical mobility, including tragus-to-
wall distance (TWD), lumbar flexion (modified Schober
index, MSI), intermalleolar distance (IMD), cervical rotation(CROT), fingertip-to-floor distance (FFD), chest expansion
(CE), and occiput-to-wall distance.17e19 The BASDAI,
BASFI, or BAS-G scores had a range of 0 to 10. Acute-phase
reactants, including ESR and CRP levels, were also measured
in the AS patients.
Samples of peripheral blood were allowed to clot and were
then centrifuged at 2400  g for 10 minutes. The sera were
frozen at e80 C immediately after sample collection. Esti-
mation of serum levels of IL-17A and IL-23 was performed
with commercial enzyme-linked immunosorbent assay
(ELISA) kits (eBioscience, San Diego, CA, USA).2.3. Statistical analysisStatistical analyses were carried out using the SPSS (17th
edition; IBM Corp., New York, NY, USA) statistical package.
The independent-samples t test was used to analyze group
differences. The Mann-Whitney U test was applied in
comparison for nonparametric analysis. Correlations between
variables were determined by Spearman’s rank correlation
test. We used receiver operating characteristic (ROC) plot
analysis to evaluate and compare the performance of each
biomarker. ROC analysis is a non-parametric method used to
quantify the accuracy of the prediction. Two-graph ROC (TG-
ROC) analysis was used to compare the whole spectrum of
sensitivity and specificity of different markers and to choose
an optimal cut-off value for each marker. A p value of 0.05
was provisionally regarded as significant.
3. Results3.1. Serum levels of IL-17 and IL-23 in AS patients and
healthy controlsThis study enrolled 49 AS patients and 25 healthy controls
(20 men and 5 women, mean age ¼ 35.1 years) who were
matched for age and sex (Table 1). We compared the serum
IL-17 and IL-23 levels between the AS patients and the
healthy controls, and both were significantly higher in the 49
AS patients than in the 25 healthy controls [IL-23: mean
(SD) ¼ 208.27 pg/mL (59.1) vs. 121.12 pg/mL (41.5),
p < 0.001; IL-17: mean (SD) ¼ 66.03 pg/mL (17.8) vs.
31.37 pg/mL (8.4), p < 0.001]. Of the AS group, 28 patients
were in the active status with a BASDAI score > 4, while 21
patients were in the inactive status. A comparison between the
active AS group, the inactive AS group and healthy controls
revealed that active AS patients had the highest levels of both
serum IL-17 and IL-23, while healthy controls had the lowest
levels, and that there were significant differences between each
group (Fig. 1).3.2. Correlations between biomarkers and clinical
parametersWe further calculated the correlation between the serum IL-
17 and IL-23 levels and clinical parameters in the 49 AS
patients (Table 2). The serum IL-17 levels did not correlate
Table 1
Demographic and disease characteristics of the 49 ankylosing spondylitis
patients.
Characteristics AS patients (n ¼ 49)
Age (y) 39.0 (12.3)
Male/female 43/6
HLA-B27 (þ) 45
C-reactive protein (mg/L) 15.08 (13.2)




Targus-to-wall (cm) 13.45 (4.5)
Modified Schober index (cm) 3.03 (1.6)
Fingertip-to-floor distance (cm) 25.00 (26.1)
Chest expansion (cm) 4.32 (2.8)
Occiput-to-wall distance (cm) 3.97 (6.4)
Intermalleolar distance (cm) 112.54 (22.9)
Disease duration (y) 9.10 (7.6)
Values are shown as mean (SD).
BASDAI ¼ Bath Ankylosing Spondylitis Disease Activity Index;
BASFI ¼ Bath Ankylosing Spondylitis Functional Index; BAS-G ¼ Bath
Ankylosing Spondylitis patient Global score.
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and disease duration. However, the serum IL-17 levels corre-
lated significantly with BASDAI (r ¼ 0.351, p ¼ 0.014) and
showed a trend toward correlating with CRP (r ¼ 0.270,
p ¼ 0.061). Serum IL-23 levels did not correlate with BASFI,
BAS-G, MSI, FFD, CE, OWD, TWD, IMD and disease
duration, but did correlate significantly with CRP (r ¼ 0.284,
p ¼ 0.048), ESR (r ¼ 0.358, p ¼ 0.012), and BASDAI score
(r ¼ 0.398, p ¼ 0.005).3.3. Use of IL-17 and IL-23 to determine disease activityFinally, we performed ROC analysis and calculated the area
under the curve (AUC) at BASDAI cut-off values of 4, 5, and 6
to evaluate the ability of IL-17, IL-23, ESR, and CRP toFig. 1. Box-and-whisker plot of the serum IL-23 and IL-17 levels of healthy control
Ankylosing Spondylitis Disease Activity Index (BASDAI) cut-off value of 4. Mann
Both serum IL-17 and IL-23 levels were significantly different between the three g
followed by inactive AS patients and healthy controls [mean (SD) ¼ 66.68 pg/mL (2
23 level were also in the same order [mean (SD) ¼ 215.36 pg/mL (52.6) vs. 202.discriminate disease activity (Fig. 2). At each BASDAI cut-
off, the two cytokines had superior discriminative ability to
the traditional biomarkers. ESR and CRP were the most
effective in the discrimination of patients with BASDAI
scores < 6 from those with BASDAI scores of  6. However,
the AUC values were only 0.611 ( p ¼ 0.326) and 0.612
( p ¼ 0.319), respectively. The best AUC was obtained from
use of IL-17 to discriminate between patients with BASDAI
scores < 6 and those with BASDAI scores of  6
(AUC ¼ 0.880, p ¼ 0.001). The best AUC value for IL-23 was
0.727 at the BASDAI cut-off of  5 ( p ¼ 0.008). IL-23 had
slightly greater AUC values than IL-17 at BASDAI cut-offs
of  4. The sensitivity, specificity, negative predictive value,
and positive predictive value in discriminating at the BASDAI
cut-off values of 4 revealed that serum cytokine levels of IL-17
and IL-23 were better at discriminating disease activity than
the traditional biomarkers (Table 3).4. Discussion
The discovery of CD4 þ Th 17 cells and related cytokines
has challenged existing paradigms and the role of Th1 T cells
in many autoimmune diseases. However, in the earlier study
by Wendling et al, the serum and synovial fluid levels of p40
IL12/23 in spondyloarthropathy patients were not significantly
different from those in normal controls.14 But other studies all
showed the possible roles of IL-17 and IL-23 in the patho-
genesis in AS. Wang et al found significantly higher serum
levels of IL-17 and IL-23 in AS patients with BASDAI
scores > 4.12 Jandus et al revealed the role of Th17 cells in the
pathogenesis of AS and psoriatic arthritis.20 Our data showed
that serum IL-17 and IL-23 levels were significantly higher in
AS patients compared with age- and gender-matched healthy
controls, and this was not limited in patients with BASDAI
scores > 4.
We also found that the serum IL-17 and IL-23 levels both
correlated with BASDAI, but did not correlate with BASFI,s, patients with active and inactive ankylosing spondylitis (AS), divided at Bath
-Whitney U test was applied in comparing the cytokine levels of three groups.
roups. (A) Patients with active AS had significantly highest serum IL-17 level
3.6) vs. 65.50 pg/mL (11.6) vs. 31.37 pg/mL (8.42), p < 0.001];( B) serum IL-
49 pg/mL (64.3) vs. 121.12 pg/mL (41.5), p < 0.001].
Table 2
Spearman’s correlation between clinical parameters and serum IL-17 and IL-23 levels in the 49 ankylosing spondylitis patients.
Clinical parameters IL-17 (pg/mL) IL-23 (pg/mL) CRP (mg/L) ESR (mm/h)
IL-23 0.015 (0.919) e e e
CRP 0.270 (0.061) 0.284 (0.048)a e e
ESR 0.032 (0.829) 0.358 (0.012)a 0.669 (<0.001)a e
BASDAI 0.351 (0.014)a 0.398 (0.005)a 0.012 (0.993) 0.078 (0.600)
BASFI 0.140 (0.342) 0.066 (0.655) 0.083 (0.573) 0.089 (0.549)
BAS-G 0.248 (0.089) 0.136 (0.358) 0.190 (0.195) 0.106 (0.475)
Disease duration 0.102 (0.537) 0.050 (0.763) 0.111 (0.501) 0.160 (0.330)
Values are shown as r ( p value). r is determined by Spearman’s rank correlation test.
BASDAI ¼ Bath Ankylosing Spondylitis Disease Activity Index; BASFI ¼ Bath Ankylosing Spondylitis Functional Index; BAS-G ¼ Bath Ankylosing Spondylitis
patient Global score; CRP ¼ C-reactive protein; ESR ¼ erythrocyte sediment rate; IL ¼ interleukin.
a p < 0.05.
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The latter parameters are related to functional ability and
spinal mobility, which are the results of the long-term
progression of new bone formation instead of the current
disease activity of AS. It is of interest that, other than its
correlation to BASDAI, IL-23 levels also have a significant
correlation to the ESR and CRP in our data, while IL-17 only
showed a non-significant trend with these two methods.Fig. 2. Receiver operating characteristic (ROC) analysis of four biomarkers in the
based on three cut-off points for the Bath Ankylosing Spondylitis Disease Activity
AUCCRP ¼ 0.530, p ¼ 0.722; AUCIL-17 ¼ 0.677, p ¼ 0.038; AUCIL-23 ¼ 0.68
AUCCRP ¼ 0.501, p ¼ 0.992; AUCIL-17 ¼ 0.675, p ¼ 0.040; AUCIL-23 ¼ 0.72
AUCCRP ¼ 0.612, p ¼ 0.319; AUCIL-17 ¼ 0.880, p ¼ 0.001; AUCIL-23 ¼ 0.7
ESR ¼ erythrocyte sedimentation rate; IL-17 ¼ interleukin-17; IL-23 ¼ interleukFurthermore, compared with ESR and CRP, the most
currently used biomarkers for disease activity, the serum IL-17
and IL-23 levels, have a better correlation with BASDAI and
worked better to discriminate between patients with higher
disease activity at BASDAI cut-off values from 4 to 6. CRP
and ESR are the most common laboratory methods for eval-
uating AS disease activity in clinical practice.21,22 An elevated
ESR or CRP level is present in only 30e40% of patients withdiagnosis of high disease activity in patients with ankylosing spondylitis (AS)
Index (BASDAI). (A) BASDAI score of  4 (AUCESR ¼ 0.581, p ¼ 0.341;
6, p ¼ 0.082); (B) BASDAI score of  5 (AUCESR ¼ 0.552, p ¼ 0.540;
7, p ¼ 0.008); (C) BASDAI score of  6 (AUCESR ¼ 0.611, p ¼ 0.326;
19, p ¼ 0.053). AUC ¼ area under the curve; CRP ¼ C-reactive protein;
in-23.
Table 3
The sensitivity, specificity, negative predictive value, and positive predictive
value of biomarkers in descriminating ankylosing spondylitis patients with
BASDAI > 4.
Cut off point Sensitivity Specificity PPV NPV
ESR 17.50 mm/h 0.643 0.5 0.643 0.5
CRP 0.9105 mg/dL 0.643 0.4 0.6 0.444
IL-17 59.4 pg/mL 0.679 0.6 0.704 0.571
IL-23 179.42 pg/mL 0.786 0.6 0.733 0.667
BASDAI ¼ Bath Ankylosing Spondylitis Disease Activity Index;
CRP ¼ C-reactive protein; ESR ¼ erythrocyte sediment rate; IL ¼ interleukin;
NPV ¼ negative predictive value; PPV ¼ positive predictive value.
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inflammation.22,23 In this study, the correlation of ESR or CRP
to BASDAI is quite poor. Consistent with previous studies,
ESR and CRP are not sufficiently capable of reflecting AS
disease activity.21,22,24 The poor discriminative ability of ESR
and CRP may be due to the complexity of AS pathogenesis.25
Serum level of IL-6, a major cytokine related to ESR or
CRP,26 was reported significantly higher in AS patients and the
level did not correlate with serum levels of IL-17 or IL-23.27
Moreover, compared with other interfering factors of inflam-
matory biomarkers, the inflammation of AS, especially axial
arthritis, might cause only mild elevation of the two acute
phase reactants in some patients. This can be supported by the
finding that there was much overlap of ESR or CRP levels
between AS patients and normal controls in our data. There-
fore, it is not surprising that ESR and CRP have an inadequate
capacity to differentiate disease activity.
In our AS cohort, we found no correlation between serum
levels of IL-17 and IL-23, contrary to expectation. However,
there was a significant correlation of IL-17 and IL-23 if
healthy controls were included in the analysis (r ¼ 0.59,
p < 0.001). Other than a small sample size, the lack of
correlation in AS patients might be because serum IL-17 is
produced by other cells in addition to Th17 cells, such as
CD4 þ Th cells,28 gd T cells,29 and mast cells.30
There are some limitations to our study. Firstly, the patient
number in our study is relatively small. The small sample size
also led to a greater male to female ratio than the expectation
(3:1). However, there was no difference between males and
females in our cohort after analysis. Furthermore, our cohort
has homogeneity in view of treatment and ethnicity, and
various parameters of AS were analyzed and determined the
potential role of IL-17 and IL-23 in the disease activity.
Secondly, this is only a cross-sectional study and we did not
follow the response to treatment and the serum IL-17 and IL-23
levels after treatment. Furthermore, we did not examine Th17
cells and other related cytokines in our study. Consequently,
further study is needed to define the role of Th17 in AS.
In conclusion, our study demonstrated that the serum IL-17
and IL-23 levels were significantly higher in AS patients than
in healthy controls and the levels correlate to disease activity
measured by BASDAI scores, but not parameters of functional
ability and spinal mobility. These results imply the role of
IL-17 and IL-23 in the pathogenesis of inflammation in AS.IL-17 and IL-23 may be potential treatment targets besides
TNF-a. However, further studies are warranted.Acknowledgments
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